Jeremy хар greener [ph] diet. Johnson & Johnson's 4Q and full year results reveal respuestas [ph] resilience amidst challenging conditions. Robust performance in consumer and medical devices offset pharmaceutical headwinds. 2010 guidance is conservative with acquisition dilutions and structured costs factored in. Revenues from recent launches and capitalizing on emerging markets present upside potential. The stock is poised for a moderate rally in the short term.

2